BackCollegium Pharmaceutical Overview
Collegium Pharmaceutical Inc

Collegium Pharmaceutical Target Price

See Collegium Pharmaceutical's analyst price targets ($48) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$23.5

Average Target Price

$48.00104.3% upside

4 analysts in the last 4 months

High: $50 | Low: $45

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-23Oppenheimer$50112.8% upsideOpen
2026-09-09Leerink Partners$4591.5% upsideOpen
2026-09-09Truist Financial$49108.5% upsideOpen
2026-08-19Barclays$48104.3% upsideOpen
2026-02-10Truist FinancialLes Sulewski$58146.8% upsideOpen
2026-01-09Barclays$56138.3% upsideOpen
2026-01-09H.C. Wainwright$60155.3% upsideOpen
2026-01-07Truist Financial$55134% upsideOpen
2025-12-08Barclays$58146.8% upsideOpen
2025-02-04Piper SandlerDavid Amsellem$3653.2% upsideOpen
2024-11-11JefferiesGlen Santangelo$4070.2% upsideOpen
2024-09-04H.C. WainwrightOren Livnat$50112.8% upsideOpen
2024-08-09Piper SandlerDavid Amsellem$3757.4% upsideOpen
2024-07-30H.C. WainwrightOren Livnat$47100% upsideOpen
2024-06-07JefferiesGlen Santangelo$4487.2% upsideOpen
2024-05-10Piper SandlerDavid Amsellem$3966% upsideOpen
2023-01-05Needham$3548.9% upsideOpen

Collegium Pharmaceutical (COLL) FAQ

Collegium Pharmaceutical's target price stands at $48. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $48 for COLL implies 104.3% upside versus today's price ($23.5). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Collegium Pharmaceutical's target price evolved across reporting periods, while the comparison chart places COLL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Collegium Pharmaceutical's reading of $48 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.